Robin K. Dore

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trial

Stanley Cohen, Robin K. Dore, Nancy E. Lane et al. · Arthritis & Rheumatism · 2008 · 570 citations

Medicine, Pharmacology, Pharmacotherapy +17

A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] with Alendronate in Postmenopausal Women with Osteoporosis

Jean‐Jacques Body, Gregory Gaich, Wim H. Scheele et al. · The Journal of Clinical Endocrinology & Metabolism · 2002 · 365 citations

Medicine, Pharmacotherapy, Bone Augmentation +16

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

Henry G. Bone, Felicia Cosman, Paul D. Miller et al. · The Journal of Clinical Endocrinology & Metabolism · 2018 · 201 citations · Full text

Medicine, Pharmacotherapy, Bone Metabolism +16

Cevimeline for the Treatment of Xerostomia in Patients With Sjögren Syndrome

Rose Fife, Walter F. Chase, Robin K. Dore et al. · Archives of Internal Medicine · 2002 · 194 citations · Full text

Dentistry, Oral Medicine, Allergy +16

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

Robin K. Dore, Stanley Cohen, Nancy E. Lane et al. · Annals of the Rheumatic Diseases · 2009 · 194 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17